Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levofloxacin

FDA-approved product (tablet, oral), marketed as Iquix, Levaquin, Levaquin In Dextrose 5% In Plastic Container and 3 more.

Registered studies
50+
Lab records
143
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Levofloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Chronic bronchitis
  • Cystic fibrosis
  • Eye infection
  • Infection
  • Pneumonia
  • Respiratory tract infectious disorder
  • Sinusitis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
FDA pharmacologic class
Fluoroquinolone Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA12; WHO ATC S01AE05; FDA class Fluoroquinolone Antibacterial

Repurposing investigation

Levofloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis91.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 7 of 7 lab records
  • K. pneumoniae: measured active in 128 of 131 lab records
  • M. tuberculosis: measured active in 4 of 4 lab records
Open Levofloxacin in ChEMBL Registered studies below
Show the 143 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levofloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

    NCT00020865 · start 2001-09

    Registered record
    Registry ID
    NCT00020865
    Conditions
    Fever, Sweats, and Hot Flashes; Infection; Leukemia; Lymphoma; Neutropenia; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    cefepime hydrochloride; levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2001-09
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFever, Sweats, and Hot Flashes; Infection; Leukemia; Lymphoma +2 more
    Interventioncefepime hydrochloride; levofloxacin
    PhasePhase 3
    Registry statusUnknown

  • Risk of Acute Liver Injury in Users of Antimicrobials

    NCT01434173 · start 2001-07

    Registered record
    Registry ID
    NCT01434173
    Conditions
    Drug-Induced Liver Injury
    Interventions
    Moxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-07
    Completion
    2009-03
    Enrolment
    1,299,056

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-Induced Liver Injury
    InterventionMoxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Compare the Safety and Effectiveness of 2 Doses of Levofloxacin Given for Different Time Periods in Patients With Pneumonia

    NCT00236821 · start 2001-03

    Registered record
    Registry ID
    NCT00236821
    Conditions
    Pneumonia
    Interventions
    levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-03
    Completion
    2002-06
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    Interventionlevofloxacin
    PhasePhase 3
    Registry statusCompleted

  • An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment

    NCT01881438 · start 2000-01

    Registered record
    Registry ID
    NCT01881438
    Conditions
    Retinal Detachment
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2000-01
    Completion
    2013-05
    Enrolment
    119,924

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Detachment
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • The Treatment of Tuberculosis in HIV-Infected Patients

    NCT00001033

    Registered record
    Registry ID
    NCT00001033
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Ethambutol hydrochloride; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride; Levofloxacin; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1997-07
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionEthambutol hydrochloride; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride +2 more
    PhasePhase 3
    Registry statusCompleted